Targeting inflammation in cardiometabolic disease: Icosapent ethyl modulates monocyte‐derived macrophages isolated from patients with cardiovascular disease with or without type 2 diabetes

Documents similaires

• A special issue on from bench to bedside: An integrated and multidisciplinary approach to tackling diabetic kidney disease
  par: Janaka Karalliedde, et autres
  Publié: (2024)
• Arterial stiffness and atherosclerosis and incident cardiovascular events and all‐cause mortality in individuals with manifest cardiovascular disease with and without type 2 diabetes
  par: Jan F. de Leijer, et autres
  Publié: (2025)
• Optimisation of care among patients with diabetes mellitus and acute coronary syndrome through a specialised cardiodiabetes service—A registry study
  par: Muhammad Usman Shah, et autres
  Publié: (2025)
• A novel approach to accurately measuring the burden of hospitalisations for cardiovascular disease in people with diabetes: A pilot study
  par: Quan Huynh, et autres
  Publié: (2024)
• Hypertensive disorders of pregnancy and gestational diabetes mellitus and predicted risk of maternal cardiovascular disease 10–14 years after delivery: A prospective cohort
  par: Kartik K. Venkatesh, et autres
  Publié: (2025)